{"organizations": [], "uuid": "7c6df102ab2115de09a27c0ff32defa1a0ca7d51", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-kadmon-receives-fda-guidance-on-pi/brief-kadmon-receives-fda-guidance-on-pivotal-clinical-trial-design-for-kd025-in-chronic-graft-versus-host-disease-idUSASC09VDZ", "country": "US", "domain_rank": 408, "title": "BRIEF-Kadmon Receives FDA Guidance On Pivotal Clinical Trial Design For KD025 In Chronic Graft-Versus Host Disease", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-10T15:01:00.000+03:00", "replies_count": 0, "uuid": "7c6df102ab2115de09a27c0ff32defa1a0ca7d51"}, "author": "", "url": "https://www.reuters.com/article/brief-kadmon-receives-fda-guidance-on-pi/brief-kadmon-receives-fda-guidance-on-pivotal-clinical-trial-design-for-kd025-in-chronic-graft-versus-host-disease-idUSASC09VDZ", "ord_in_thread": 0, "title": "BRIEF-Kadmon Receives FDA Guidance On Pivotal Clinical Trial Design For KD025 In Chronic Graft-Versus Host Disease", "locations": [], "entities": {"persons": [{"name": "pivotal clin", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "chronic graft-versus host disease reuters", "sentiment": "none"}, {"name": "kadmon holdings inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 10, 2018 / 12:02 PM / Updated 8 minutes ago BRIEF-Kadmon Receives FDA Guidance On Pivotal Clinical Trial Design For KD025 In Chronic Graft-Versus Host Disease Reuters Staff \nApril 10 (Reuters) - Kadmon Holdings Inc: * HOST DISEASE \n* ARM, PIVOTAL PHASE 2 CLINICAL TRIAL TO SUPPORT POTENTIAL REGISTRATION OF KD025 IN CGVHD Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-10T15:01:00.000+03:00", "crawled": "2018-04-10T15:17:04.006+03:00", "highlightTitle": ""}